Evidence map›Paper›PMID 19508730›Full record

ArticleBMC cancer2009

Cytoplasmic Kaiso is associated with poor prognosis in non-small cell lung cancer.

Shun-Dong Dai, Yan Wang, Yuan Miao, Yue Zhao, Yong Zhang, Gui-Yang Jiang, Peng-Xin Zhang, Zhi-Qiang Yang, En-Hua Wang

Abstract read
In one paragraph

Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Prognostic value of matrix metalloproteinase-7 expression in patients with non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  2. Article
  3. Association of Kaiso and partner proteins in oral squamous cell carcinoma.Journal of Taibah University Medical Sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Dancing from bottoms up - Roles of the POZ-ZF transcription factor Kaiso in Cancer.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Kaiso mainly locates in the nucleus in vivo and binds to methylated, but not hydroxymethylated DNA.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015
    Article
  19. Distribution of Kaiso protein in mouse tissues.Histochemistry and cell biology · 2015
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shun-Dong DaiDepartment of Pathology, College of Basic Medical Sciences and First Affiliated Hospital of China Medical University, Shenyang, PR China. dddsddd111@yahoo.com.cn
Yan Wang
Yuan Miao
Yue Zhao
Yong Zhang
Gui-Yang Jiang
Peng-Xin Zhang
Zhi-Qiang Yang
En-Hua Wang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKaiso has been identified as a new member of the POZ-zinc finger family of transcription factors that are implicated in development and cancer. Although controversy still exists, Kaiso is supposed to be involved in human cancer. However, there is limited information regarding the clinical significance of cytoplasmic/nuclear Kaiso in human lung cancer.

methodsIn this study, immunohistochemical studies were performed on 20 cases of normal lung tissues and 294 cases of non-small cell lung cancer (NSCLC), including 50 cases of paired lymph node metastases and 88 cases with complete follow-up records. Three lung cancer cell lines showing primarily nuclear localization of Kaiso were selected to examine whether roles of Kaiso in cytoplasm and in nucleus are identical. Nuclear Kaiso was down-regulated by shRNA technology or addition a specific Kaiso antibody in these cell lines. The proliferative and invasive abilities were evaluated by MTT and Matrigel invasive assay, transcription of Kaiso's target gene matrilysin was detected by RT-PCR.

resultsKaiso was primarily expressed in the cytoplasm of lung cancer tissues. Overall positive cytoplasmic expression rate was 63.61% (187/294). The positive cytoplasmic expression of Kaiso was higher in advanced TNM stages (III+IV) of NSCLC, compared to lower stages (I+II) (p = 0.019). A correlation between cytoplasmic Kaiso expression and lymph node metastasis was found (p = 0.003). In 50 paired cases, cytoplasmic expression of Kaiso was 78.0% (41/50) in primary sites and 90.0% (45/50) in lymph node metastases (p = 0.001). The lung cancer-related 5-year survival rate was significantly lower in patients who were cytoplasmic Kaiso-positive (22.22%), compared to those with cytoplasmic Kaiso-negative tumors (64.00%) (p = 0.005). Nuclear Kaiso staining was seen in occasional cases with only a 5.10% (15/294) positive rate and was not associated with any clinicopathological features of NSCLC. Furthermore, after the down-regulation of the nuclear expresses Kaiso in vitro, both proliferative and invasive abilities of three cancer cell lines were significantly enhanced, along with the up-regulation of Kaiso target gene, matrilysin.

conclusionOur data suggest cytoplasmic Kaiso expression is associated with poor prognosis of NSCLC and various subcellular localizations of Kaiso may play differential biological roles in NSCLC.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCell Line, TumorCytoplasmFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLung NeoplasmsLymphatic MetastasisMaleMatrix Metalloproteinase 7Middle AgedRNA, Small InterferingMatrix Metalloproteinase 7MMP7 protein, humanRNA, Small InterferingTranscription FactorsZBTB33 protein, human

Identifiers

PMID19508730
PMCPMC2701439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.